Zacks.com on MSN4h
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...
GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell ...
Pharmaceutical Technology on MSN14h
MSD secures worldwide license for LaNova’s LM-299
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
FiercePharma13h
Fierce Pharma Asia—Merck and BioNTech's I-O bispecific buys; AZ CEO's China defense
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
MM&M12h
Rx Rundown: Roche, Metsera, Intercept Pharmaceuticals and more
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Genscript Biotech Strikes Lucrative Licensing Deal
Genscript Biotech (HK:1548) has released an update. Genscript Biotech’s subsidiary, Probio Nanjing, has entered into a significant ...
Zacks.com on MSN5h
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
PipelineReview.com18h
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
RAHWAY, NJ, USA I 14, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately ...